Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.
2.

Protein misfolding in disease and small molecule therapies.

Gomes CM.

Curr Top Med Chem. 2012;12(22):2460-9. Review.

PMID:
23339300
3.

Small-molecule modulation of cellular chaperones to treat protein misfolding disorders.

Sloan LA, Fillmore MC, Churcher I.

Curr Opin Drug Discov Devel. 2009 Sep;12(5):666-81. Review.

PMID:
19736625
4.

Screening methods for identifying pharmacological chaperones.

Shin MH, Lim HS.

Mol Biosyst. 2017 Mar 28;13(4):638-647. doi: 10.1039/c6mb00866f. Review.

PMID:
28265599
5.

Repair of CFTR folding defects with correctors that function as pharmacological chaperones.

Loo TW, Clarke DM.

Methods Mol Biol. 2011;741:23-37. doi: 10.1007/978-1-61779-117-8_3.

PMID:
21594776
6.
7.

Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease.

Amaral MD.

J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):477-87. Review.

PMID:
16763920
8.
9.

Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators.

Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW.

J Inherit Metab Dis. 2014 Jul;37(4):505-23. doi: 10.1007/s10545-014-9701-z. Epub 2014 Apr 1. Review.

PMID:
24687294
10.

Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.

Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, Riordan JR, Kelly JW, Yates JR 3rd, Balch WE.

Cell. 2006 Nov 17;127(4):803-15.

11.

The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease.

Duncan EJ, Cheetham ME, Chapple JP, van der Spuy J.

Subcell Biochem. 2015;78:243-73. doi: 10.1007/978-3-319-11731-7_12. Review.

PMID:
25487025
12.

Emerging novel concept of chaperone therapies for protein misfolding diseases.

Suzuki Y.

Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(5):145-62. Review.

14.

Molecular chaperones in cellular protein folding.

Hartl FU, Martin J.

Curr Opin Struct Biol. 1995 Feb;5(1):92-102. Review.

PMID:
7773752
15.

Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.

Brooks DA.

Semin Cell Dev Biol. 1999 Oct;10(5):441-2. No abstract available.

PMID:
10597626
16.

In vivo aspects of protein folding and quality control.

Balchin D, Hayer-Hartl M, Hartl FU.

Science. 2016 Jul 1;353(6294):aac4354. doi: 10.1126/science.aac4354. Review.

PMID:
27365453
17.

Biological and structural basis for Aha1 regulation of Hsp90 ATPase activity in maintaining proteostasis in the human disease cystic fibrosis.

Koulov AV, LaPointe P, Lu B, Razvi A, Coppinger J, Dong MQ, Matteson J, Laister R, Arrowsmith C, Yates JR 3rd, Balch WE.

Mol Biol Cell. 2010 Mar 15;21(6):871-84. doi: 10.1091/mbc.E09-12-1017. Epub 2010 Jan 20.

18.

Targeting Molecular Chaperones for the Treatment of Cystic Fibrosis: Is It a Viable Approach?

Heard A, Thompson J, Carver J, Bakey M, Wang XR.

Curr Drug Targets. 2015;16(9):958-64. Review.

PMID:
25981601
19.

High-throughput screening of libraries of compounds to identify CFTR modulators.

Pedemonte N, Zegarra-Moran O, Galietta LJ.

Methods Mol Biol. 2011;741:13-21. doi: 10.1007/978-1-61779-117-8_2.

PMID:
21594775
20.

Pharmacological correction of misfolding of ABC proteins.

Rudashevskaya EL, Stockner T, Trauner M, Freissmuth M, Chiba P.

Drug Discov Today Technol. 2014 Jun;12:e87-94. doi: 10.1016/j.ddtec.2014.03.009. Review.

Supplemental Content

Support Center